Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape

Keyphrases

• Chronic Lymphocytic Leukemia 100%
• Microenvironment 100%
• Therapeutic Landscapes 100%
• B-cell Receptor Signaling 60%
• Cell Expansion 40%
• Translational Research 20%
• Small Molecule Inhibitors 20%
• Malignancy 20%
• Cancer Cells 20%
• Disease Progression 20%
• Lymphatic Tissue 20%
• Cell Survival 20%
• B Cells 20%
• Chronic Lymphocytic Leukemia Cells 20%
• Solid Cancer 20%
• Leukemia Therapy 20%
• Therapeutic Advances 20%
• Tumor Microenvironment 20%
• External Signal 20%
• Cancer Genome 20%
• Hematological Cancer 20%
• Posters 20%
• Proliferation Centers 20%
• Germinal Center 20%
• Normal B Cells 20%
• Genetic Lesions 20%
• Multikinase Inhibitor 20%
• Ibrutinib 20%
• Bruton Tyrosine Kinase Inhibitor 20%
• Conserved Mechanisms 20%
• Signaling Kinases 20%
• Tissue Areas 20%
• Phosphoinositide-3-kinase delta Inhibitor 20%
• GS-1101 20%

Medicine and Dentistry

• B-Cell Chronic Lymphocytic Leukemia 100%
• B Lymphocyte Receptor 50%
• Cancer 33%
• Cell Expansion 33%
• Malignant Neoplasm 16%
• Cancer Cell 16%
• Lymphatic Tissue 16%
• Disease Exacerbation 16%
• Leukemia Cell 16%
• Cell Survival 16%
• B Cell 16%
• Kinase Signaling 16%
• Tumor Microenvironment 16%
• Translational Research 16%
• Phosphoinositide 3-Kinase 16%
• Germinal Center 16%
• Phosphotransferase Inhibitor 16%
• Ibrutinib 16%
• Bruton Tyrosine Kinase Inhibitor 16%